Gene Therapy in China: What Is Labelled, What Is a Cancer Shot Ad
Gene therapy in China is not a pan-cancer shot and not a synonym for CAR-T. Labelled: historic Gendicine/Oncorine for named head-and-neck uses, and BBM-H901 (dalnacogene ponparvovec) NMPA 10 April 2025 for adult haemophilia B. Send a product name or trial ID. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
Product name firstnot a gene SKU
BBM-H90110 Apr 2025 label
Not CAR-Tdifferent desk
Quick answer
Gene therapy in China is not a pan-cancer shot and not a synonym for CAR-T or a diabetes stem-cell ad. What is labelled: historic Gendicine (rAd-p53, 2003-2004) and Oncorine (H101, 2005) for named head-and-neck uses, and BBM-H901 (dalnacogene ponparvovec) NMPA 10 April 2025 for adult moderate-to-severe haemophilia B. Onasemnogene (Zolgensma) was still in a China filing / priority-review track as of August 2025 reports — not a walk-in adult-oncology SKU. Send a product name or NCT/ChiCTR ID. About 24 hours. No obligation to book.
Three searches, three desks
| What people say | What it usually is | Where it belongs |
|---|---|---|
| Gendicine / p53 adenovirus | 2003 China approval; combined cancer use; not a universal cure | This page — named indication only |
| Oncolytic virus / gene-modified ‘new’ product | Mostly registered trials | This page if an ID exists; otherwise stop |
| CAR-T / satri-cel | Cell therapy, not classic gene therapy | CAR-T page |
| ‘China diabetes gene/stem-cell cure’ | Headline vs standard endocrinology | Diabetes page |
Cost
No single gene-therapy SKU. Do not apply blood-cancer CAR-T bands here unless the file is actually CAR-T. Cost checklist
Centres
Oncology gene/cell questions are compared at high-volume units (CAMS/NCC, PKU Cancer, Fudan) after the product is named — not from a brochure. Hospitals
What actually changes the plan
📋
Name the product or the paper
Gendicine, an oncolytic trial ID, or a mislabelled CAR-T/stem-cell ad. Three different desks.
🏥
Licensed vs trial vs wrong URL
We route cell therapy to the CAR-T page and diabetes headlines to diabetes. This page stays gene-modified products.
✈️
No SKU price
Travel only after a centre will review the named indication. Invitation and visa follow that letter.
What this page helps you decide
✅
Gendicine kept in its box
2003 approval, combined use, not a universal cancer gene cure.
💬
CAR-T not sold here
Satri-cel and blood-cancer CAR-T stay on their own URL with their own RMB/USD bands.
🌍
Trial claims must carry an ID
No NCT/ChiCTR, no travel recommendation.
Evidence table
NMPA BBM-H901 and Nature Medicine ABR vs historic adenoviruses vs CAR-T mix-ups.
| Source | What it says | Relevance to patients |
|---|---|---|
| NMPA BBM-H901 (10 Apr 2025) | Adult moderate-severe haemophilia B, AAV FIX-Padua | Rare-disease gene therapy. Not cancer. Not type 1 diabetes. |
| Nature Medicine (2025-26) | Phase 3 n=26, ABR 0.60 vs margin 5.0 | Bleed-rate drop in a selected cohort, not a guaranteed lifelong cure. |
| Gendicine / Oncorine labels (2003-05) | Named HNSCC / nasopharyngeal adenovirus products | Old, histology-specific. Not a pan-cancer gene shot. |
| CDE onasemnogene filing (Aug 2025) | NDA accepted / priority review reported | Not treated here as a granted adult-cancer label. |
| CDE gene-therapy classification (2026) | Scope and classification guideline (notice no. 40) | The licensed indication has to match the classified product. |
Who this page is for
Patients who searched 'gene therapy China'
Need the Gendicine / trial / CAR-T split before they buy a package name.
Oncology files after standard lines
Need to know if any gene-modified or oncolytic protocol is even open to foreigners.
Families holding a diabetes or CAR-T headline
Need a redirect to the correct page, not a third invented product.
What you can actually book
A product-level screen: haemophilia B AAV at designated haematology units, or a named HNSCC combined plan, or a trial ID. Related: CAR-T, what “cure” means.
What moves the cost
Claim and file screen
No charge to start
Licensed vs trial vs wrong URL • Product/ID check • Where to send the file
Coordinated review trip
Only if a centre will see you
Introduction • Itemised drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send the file and the claim
Pathology plus the product name, paper or ad you saw. We label licensed / trial / marketing.
02
Route to the right desk
Stay here, move to CAR-T, move to diabetes, or stop. Wrong desk is how money is wasted.
03
Travel only after written interest
Invitation, visa length, interpreter. Gene-modified protocols are not walk-in infusions.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
Is there gene therapy for cancer in China?
Historic Gendicine and Oncorine are labelled for named head-and-neck uses, not a pan-cancer shot. CAR-T is a different desk. Do not buy a mixed PDF.
What is BBM-H901?
Dalnacogene ponparvovec, NMPA 10 April 2025, for adult moderate-to-severe haemophilia B. Nature Medicine phase 3: mean ABR 0.60 vs a margin of 5.0 in 26 participants.
Is Zolgensma approved in China?
As of August 2025 filing reports, onasemnogene was in a China NDA / priority-review track. We do not treat that as a granted adult-oncology label.
Is gene therapy the same as CAR-T?
No.
What does haemophilia B gene therapy cost?
High-value rare-disease product. Commercial access has been messy (Takeda-Belief arrangement publicly ended August 2026). We do not quote a tourism price.
What records should I send?
Product name or NCT/ChiCTR ID, diagnosis, AAV serology if relevant.
Will you book Gendicine as a cancer cure?
No.
Do you hold vials?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
“Gene therapy for cancer in China” that is actually Gendicine marketing, a CAR-T mix-up, or an unnamed plasmid. We will not book a wellness hotel as a gene-therapy centre.
Gene therapy sold for diabetes or “all cancers.”
No AAV serology, no product name.
CAR-T and Gendicine mixed in one PDF.
Pay for vials before a designated centre accepts the file.
Sources
NMPA BBM-H901, 10 April 2025; Molecular Therapy editorial.
Zhang / Yang et al., Nature Medicine — ABR 0.60 vs margin 5.0.
Chinese AAV haemophilia B clinical guidance (2025) on antibodies and irreversibility.
Historic Gendicine and Oncorine labels; CDE 2026 classification guideline; August 2025 onasemnogene filing reports.
A treating haematologist should review the file before travel. This page is matching information, not an infusion booking.
Freshness label on this page: 2026-08-15